Jim Simons Cassava Sciences Inc Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 10, 2021	SELL	$6.79 - $12.25 $762,517 - $1.38 Million	-112,300 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$2.86 - $11.51 $321,178 - $1.29 Million	112,300 New	112,300 $1.29 Million
Q2 2020 Aug 13, 2020	SELL	$2.04 - $9.64 $1.33 Million - $6.3 Million	-653,759 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$3.26 - $9.65 $1.18 Million - $3.49 Million	-362,000 Reduced 35.64%	653,759 $2.69 Million
Q4 2019 Feb 13, 2020	BUY	$1.1 - $6.12 $180,181 - $1 Million	163,801 Added 19.23%	1,015,759 $5.28 Million
Q3 2019 Nov 13, 2019	BUY	$1.04 - $1.45 $175,932 - $245,290	169,166 Added 24.78%	851,958 $1.02 Million
Q2 2019 Aug 12, 2019	BUY	$1.02 - $1.34 $100,878 - $132,526	98,900 Added 16.94%	682,792 $826,000
Q1 2019 May 14, 2019	BUY	$0.92 - $1.29 $537,180 - $753,220	583,892 New	583,892 $753,000

189

13.5M

1.38M

2.26M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.08B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.